Saad Sirop Kenderian

Physician, Scientist, Innovator Hematology, Oncology, Bone Marrow Transplant, Immunology, Molecular Medicine, Regenerative Medicine

Saad Sirop Kenderian is a prominent figure in the field of cancer research and treatment, currently serving as the Co-Leader of Cancer Immunology and Immunotherapy at the Mayo Clinic Comprehensive Cancer Center. His work focuses on advancing immunotherapy techniques, particularly in the context of CAR-T cell therapy, which is a groundbreaking approach in treating various cancers.

Education and Certifications

Medical Degree: MBChB with First Honors from the University of Baghdad School of Medicine (2003).
Board Certifications:
- American Board of Internal Medicine (2009)
- Medical Oncology (2013)
- Hematology (2013)
Additional Certification: Educational Committee for Foreign Medical Graduates Certificate (2005).

Research and Contributions

Kenderian has made significant contributions to understanding and improving chimeric antigen receptor (CAR) T-cell therapies. His research has identified critical checkpoints like PD1 and TIM3 that limit the efficacy of these therapies in leukemia, leading to advancements in treatment protocols. He has received multiple awards for his research, including:

Abstract Achievement Award from the American Society of Hematology (2015).
Best Abstract Award from the American Society for Blood and Marrow Transplantation (2016).
NCCN Young Investigator Award (2017).

Professional Recognition

Throughout his career, Kenderian has been recognized for his exceptional contributions to medicine and research. He has received numerous accolades, including:

Outstanding Hem/Onc Fellow Achievement Award from Mayo Clinic (2013).
Chief Fellow Award from Mayo Clinic (2013).
New Investigator Award from Mayo Clinic (2018).

Current Role and Impact

In his role at Mayo Clinic, Kenderian leads initiatives aimed at enhancing cancer treatment through innovative immunological strategies. He is actively involved in mentoring young scientists and promoting equitable access to cancer therapies. His commitment to research and education positions him as a key contributor to the ongoing advancements in cancer care.

Kenderian's LinkedIn profile reflects his extensive network and ongoing engagement with the scientific community, showcasing his dedication to collaboration and knowledge sharing in the field of cancer immunology.1